According to a document from the Drug Administration of Vietnam, the mass media has reflected the sale of drugs to treat COVID-19 without a doctor’s prescription, including the drug Molnupiravir.
Molnupiravir is conditionally licensed, is a prescription drug, and needs to continue to be monitored for its quality, effectiveness and safety during circulation. The use of Molnupiravir drug requires examination, prescription and guidance of a physician.
According to the Drug Administration of Vietnam, the purchase, sale and use of Molnupiravir in contravention of regulations on prescription is a serious violation of the provisions of the Law on Pharmacy and has the potential to adversely affect people’s health and reduce the effectiveness of prevention. anti-epidemic.
In order to ensure the safety of users, strictly implement the 2016 Pharmacy Law and rectify the situation of violations of the law on prescribing and selling prescription drugs in the circulation of drugs to treat COVID-19, the Drug Administration of Vietnam requests the Department of Health to Ho Chi Minh City Health Department continued to fully implement the instructions on selling drugs by prescription, including Molnupiravir in previous documents of the Ministry of Health, Drug Administration of Vietnam; as well as guidelines on inspection and strengthening of management of the purchase and sale of drugs to treat COVID-19.
Directing the Inspector of the Department of Health to coordinate with functional units of the Department to urgently inspect the distribution and distribution of Molnupiravir at the drugstore system in the city.
Handle according to their competence or propose competent agencies to strictly handle violations.
Results of inspection, verification and handling of violations (if any), the Department of Health of Ho Chi Minh City shall report to the Drug Administration of Vietnam before March 30, 2022, and at the same time, notify the press agency according to its competence. .
According to the latest update of the Ministry of Health’s guidance, Molnupiravir is indicated for adult COVID-19 patients aged 18 years and older with mild to moderate severity and at least one risk factor for severe disease progression. .
Drugs containing Molnupiravir are new, conditionally licensed, prescription drugs that need to continue to be monitored for the quality, effectiveness and safety of the drug during circulation. The use of Molnupiravir drug requires examination, prescription and guidance of doctors and medical staff.
Molnupiravir must not be used for more than 5 days in a row. Molnupiravir is not used for post- or pre-exposure prophylaxis against COVID-19. Do not use Molnupiravir for pregnant women, nursing women, children under 18 years old due to concerns about the risk of toxicity on the fetus, on bones and cartilage of the drug. People should not worry, do not arbitrarily buy or use the drug Molnupiravir floating, of unknown origin, of origin on the market, only using drugs that have been licensed for circulation by the Ministry of Health to ensure quality, effectiveness of treatment and their own health. The improper use of drugs will affect the treatment of the disease and pose a potential risk of direct health effects due to the risk of adverse drug reactions.
Source: CafeF
Source: Vietnam Insider